BI 1516-0003 – a phase Ib, multicentre, randomised, double-blind, placebo-controlled 2 sequence crossover trial to evaluate the effects of BI 3031185 on safety, tolerability, pharmacodynamics, and pharmacokinetics in patients with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD)